Biofrontera (BFRI) Non Operating Investment Income (2022 - 2026)
Biofrontera (BFRI) posted quarterly Non Operating Investment Income of -$1000.0 for Q4 2025, up 50.0% year-over-year from -$666.67 in Q4 2024, and down 200.0% quarter-over-quarter from $1000.0 in Q3 2025.
Biofrontera (BFRI) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Biofrontera's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$1000.0 for Q4 2025.
- In Q4 2025, Non Operating Investment Income rose 50.0% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$1000.0 (up 99.87% YoY), while the FY2025 annual figure was $2000.0, up 114.29% from the prior year.
- Non Operating Investment Income for Q4 2025 stood at -$1000.0, down from $1000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $1.7 million in Q4 2022, with the low at -$2.9 million in Q1 2023.
- The 4-year median for Non Operating Investment Income is -$2000.0 (2024), against an average of -$473916.7.
- The sharpest annual moves came in 2023 and 2025: Non Operating Investment Income tumbled 144.99% in 2023, then surged 150.0% in 2025.
- Biofrontera's Non Operating Investment Income stood at $1.7 million in 2022, then sank by 144.99% to -$786000.0 in 2023, then surged by 99.75% to -$2000.0 in 2024, then jumped by 50.0% to -$1000.0 in 2025.
- Business Quant data shows BFRI's Non Operating Investment Income at -$1000.0 in Q4 2025, $1000.0 in Q3 2025, and $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Biofrontera | 19.06 Mn | 14.35 Mn | 9.59 Mn | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | -786,000.00 |
| Dec 31, 2023 | -786,000.00 |
| Sep 30, 2023 | -2.21 Mn |
| Sep 30, 2023 | -2.21 Mn |